**Article**

**Chronic kidney disease–associated pruritus is caused by dysregulated ion channels in sensory neurons**

Akishi Momose1,*, Micchihiro Yabe1, Shigetoshi Chiba1, Kenjiro Kumakawa1 and Yasuo Shiraiwa1, Hiroki Mizukami2

1 Department of Urology, Jusendo General Hospital, 9638585 Koriyama, Japan; mail@jusendo.or.jp
2 Department of Pathology and Molecular Medicine, Hirosaki University Graduate School of Medicine, 0368563 Hirosaki, Japan; imair@hirosaki-u.ac.jp

*Correspondence: a.momose@jusendo.or.jp; Tel.: +81-0249-32-6363

**Abstract.** Background: We investigated ion channels at the skin, including peripheral nerve endings, which serve as output machines and molecular integrators of many pruritic inputs mainly received by multiple G protein-coupled receptors (GPCRs). Methods: Based on the level of chronic kidney disease–associated pruritus (CKD-aP), subjects were divided into two groups: non-CKD-aP (no or slight pruritus; n=12) and CKD-aP (mild, moderate, or severe pruritus; n=11). Skin samples were obtained from the forearm or elbow during operations on arteriovenous fistulas. We measured ion channels expressed at the skin, including peripheral nerve endings by RT-PCR: Nav1.8, Kv1.4, Cav2.2, Cav3.2, BKCa, Anoctamin1, TRPV1, TRPA1, and ASIC. Results: Expression of Cav3.2, BKCa, and anoctamin1 was significantly elevated in patients with CKD-aP. On the other hand, expression of TRPV1 was significantly reduced in these patients. We observed no significant difference in the levels of Cav2.2 or ASIC between subjects with and without CKD-aP. TRPA1, Nav1.8, and Kv1.4 were not expressed. Conclusions: It was concluded that this greater difference in expression of ion channels at the skin tissue including specific for cutaneous peripheral nerve endings in CKD patients with CKD-aP may increase generator potential related to itching.

**Keywords:** uremic pruritus; ion channels; cell signaling; Cav3.2 calcium channel; RT-PCR; skin

**1. Introduction**

Itching can be caused by various stimuli, including mechanical, electrical, and chemical stimuli. Exogenous and endogenous chemical stimuli include amines, proteases, neuropeptides, inflammatory mediators, and certain drugs. However, in previous studies that compared immunostaining skin sections treated with various common pruritogens (histamine, acetylcholine [ACh], etc.), uremic substances, and other substances causing itching (e.g. β-endorphin and endothelin-1), no significant difference was observed between patients with and without CKD-aP, even though the immunostaining epidermis sections were stained regardless of CKD-aP [1].

Among uremic substances, for example, endothelin-1, which is classified of moderate molecular weight, and para-cresyl sulfate, a protein-bound uremic toxin, have been reported as candidate substances that cause itching in patients with chronic kidney disease (CKD)-associated pruritus (CKD-aP) [2,3]. Although CKD patients undergo hemodialysis with high-performance membrane or on-line hemodiafiltration, as well as long-term or frequent hemodialysis, to remove these uremic substances, approximately 40% of patients still suffer from CKD-aP. [4].

These findings suggested that itching can be caused by receptors and other signals, instead of pruritogens. So, we first examined the downstream ion channels because it is difficult to measure the complex and many downstream signals from ligands (pruritogens). Expressed ion channels in cutaneous peripheral nerve endings in healthy individuals are as follows: among the voltage-gated Na+ channels (Nav), Nav1.7, Nav1.8, and Nav1.9; among the voltage-gated K+ channels, Kv1.4, Kv3.4, and Kv7.2 (Kv); among the Ca2+-activated K+ channels (KCa), big conductance (BKCa); among the two-pore K+ channels, TREK1 and TRAAK; among the voltage-gated Ca+ channels (Cav), N-type

---

© 2019 by the author(s). Distributed under a Creative Commons CC BY license.
(Cav2.2) and T-type (Cav3.2); among the Cl channels, calcium-activated chloride channel Anoctamin1 (TMEM16A); among the transient receptor potential (TRP) channels, TRP vanilloid 1 (TRPV1) and TRP ankyrin 1 (TRPA1); and acid-sensing ion channels (ASIC1) [5,6]. Among these channels, Nav1.8, Kv1.4, BKCa, Cav2.2, and Cav3.2 are expressed only in the cutaneous peripheral nerve endings, whereas TRPV1, TRPA1, Anoctamin1, BKCa, and ASIC are expressed not only in the peripheral nerve cells but also in keratinocytes at the skin.

Our goal was to test the hypothesis that the output of multiple ion channels is associated with itching or pain. To explore the peripheral neuronal mechanisms underlying itching, we compared the expression of several ion channels at the skin, including peripheral nerve endings between CKD patients with and without CKD-aP.

2. Materials and Methods

2.1. Subjects

This cohort-sectional study was approved by the Ethics Committee of Jusendo General Hospital. Each patient gave written informed consent. Between February 2016 and September 2018, we performed arteriovenous fistula surgery in 77 patients with CKD stage 5, either before the induction of hemodialysis (HD) or within 1 month after the induction of HD. Twenty-three patients (8 females and 15 males, 38–86 years old) and one control agreed to participate in the study. The control was a patient undergoing an operation for prostatic hypertrophy, who reported no pruritus. Patients with concomitant dermatitis, e.g., atopic dermatitis or psoriasis, were excluded. The degree of pruritus was determined according to Shiratori’s Japanese classification of itching (Table 1). When the degree of pruritus was different between daytime and nighttime, a larger value of score was defined as the pruritus score. Based on the level of pruritus, subjects were divided into two groups: non-CKD-aP (no or slight pruritus; n=12) and CKD-aP (mild, moderate, or severe pruritus; n=11).

<table>
<thead>
<tr>
<th>Score (severity)</th>
<th>Daytime symptoms</th>
<th>Nighttime symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 (severe)</td>
<td>Intolerable itching, worsened instead of relieved by scratching. Cannot focus on work or study</td>
<td>Can hardly sleep because of itching. Scratching all the time, but itching intensifies with scratching</td>
</tr>
<tr>
<td>3 (moderate)</td>
<td>Scratching even in the presence of others. Irritation as a result of itching, continuous scratching</td>
<td>Wake up because of itching. Can fall asleep again after scratching, but continue to scratch unconsciously while sleeping</td>
</tr>
<tr>
<td>2 (mild)</td>
<td>Itch sensation is relieved by light, occasional scratching. Not too disturbing</td>
<td>Feel somewhat itchy, which is relieved by scratching. Do not wake up because of itch sensations</td>
</tr>
<tr>
<td>1 (slight)</td>
<td>Feel slightly itchy sometimes, but tolerable without scratching</td>
<td>Feel slightly itchy when going to sleep, but do not need to scratch. Sleeping well</td>
</tr>
<tr>
<td>0 (no symptoms)</td>
<td>Hardly feel itchy or do not feel itchy at all</td>
<td>Hardly feel itchy or do not feel itchy at all</td>
</tr>
</tbody>
</table>

2.2. Study designs

We compared age, gender, underlying disease, presence of hepatitis B or C, number of patients receiving treatment for itching, as well as levels of blood serum albumin, corrected Ca, inorganic phosphorus, intact parathyroid hormone (intact-PTH), blood serum hypersensitive C-reactive protein (hs-CRP), and blood ferritin in patients of the pruritus and non-pruritus groups.

Skin samples about 10 × 5 mm² were obtained from the forearm or elbow immediate after commencing operations on the arteriovenous fistulae.

2.3. Quantitative real-time polymerase chain reaction (RT-PCR)
Expressed ion channels in cutaneous peripheral nerve endings in healthy individuals are as follows: among the voltage-gated Na+ channels (Nav), Nav1.7, Nav1.8, and Nav1.9; among the voltage-gated K+ channels, Kv1.4, Kv3.4, and Kv7.2 (Kv); among the Ca2+-activated K+ channels (KCa), big conductance (BKca); among the two-pore K+ channels, TREK1 and TRAAK; among the voltage-gated Ca+ channels (Cav), N-type (Cav2.2) and T-type (Cav3.2); among the Cl channels, calcium-activated chloride channel Anoctamin1 (TMEM16A); among the transient receptor potential (TRP) channels, TRP vanilloid 1 (TRPV1) and TRP ankyrin 1 (TRPA1); and acid-sensing ion channels (ASIC1) [5,6]. Among the ion channels expressed in cutaneous peripheral nerve endings, we measured the levels of Nav1.8 (SCN10A), Kv1.4 (KCNA4), BKca (KCNMA1), Cav2.2 (CACNA1B), Cav3.2 (CACNA1H), Anoctamin1 (TREM16A), TRPV1, TRPA1, and ASIC by RT-PCR. Nav1.8, Kv1.4, Cav2.2, and Cav3.2 are expressed only in the cutaneous peripheral nerve endings, whereas TREM16A, TRPV1, TRPA1, ASIC1, and BKca are expressed not only in the peripheral nerve cells but also in keratinocytes at the skin.

Gene expression levels for ion channels were determined after reverse transcription of RNA samples by quantitative PCR by using an ABI PRISM 7000 Sequence Detector (Thermo Fisher Scientific, MA USA) as described previously [10]. Pre-made TaqMan® Gene Expression Assays for human were used (Thermo Fisher Scientific). Total RNA was isolated from the biopsied skin specimens with TRlzol (Thermo Fisher Scientific). cDNA was synthesized from total RNA with reverse transcriptase reaction using SuperScript™ VI LÔTMaster Mix (Thermo Fisher Scientific) following the manufacturer’s protocol. cDNA was synthesized from 1 μg of total RNA. For standardization of quantitation, beta 2-microglobulin as amplified simultaneously. The expression level of each gene is presented as fold increase in the subjects showing itchy compared with control subject.

Table 2. Gene Assays ID.

<table>
<thead>
<tr>
<th>Gene name</th>
<th>Assay ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASIC1 (acid sensing ion channel subunit 1)</td>
<td>Hs00952807_m1</td>
</tr>
<tr>
<td>Anoctamin 1</td>
<td>Hs00216121_m1</td>
</tr>
<tr>
<td>CACNA1B (Cav2.2)</td>
<td>Hs04996252_m1</td>
</tr>
<tr>
<td>CACNA1H (Cav3.2)</td>
<td>Hs01103527_m1</td>
</tr>
<tr>
<td>KCNA4 (Kv1.4)</td>
<td>Hs00937357_s1</td>
</tr>
<tr>
<td>KCNMA1 (BKca)</td>
<td>Hs01119504_m1</td>
</tr>
<tr>
<td>SCN10A (Nav1.8)</td>
<td>Hs01045151_m1</td>
</tr>
<tr>
<td>TRPA1</td>
<td>Hs00175798_m1</td>
</tr>
<tr>
<td>TRPV1</td>
<td>Hs00218912_m1</td>
</tr>
<tr>
<td>beta-2-microglobulin</td>
<td>Hs00187842_m1</td>
</tr>
</tbody>
</table>

Pre-made TaqMan® Gene Expression Assays for human were used (Thermo Fisher Scientific, MA USA).

2.4. Statistical analysis

All values are expressed as means ± standard deviations (SD) for normally distributed data, medians (ranges) for non-normally distributed data, and numbers (percentages). No data points were excluded. All statistical analyses were performed using the unpaired t-test or m×n chi-square test for categorical outcomes. P-values < 0.05 were considered to be statistically significant.

3. Results

3.1. Baseline characteristics

No differences were observed between the two groups in term of age, gender, underlying disease, duration of renal replacement therapy, presence of hepatitis B or C, number of patients
receiving treatment for itching, or the levels of corrected Ca, inorganic phosphorus, blood serum albumin, blood serum hsCRP, and blood serum ferritin (Table 3).

Table 3. Patient characteristics.

<table>
<thead>
<tr>
<th></th>
<th>Non-pruritus (n=12)</th>
<th>Pruritus (n=11)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Degree of pruritus</td>
<td>none, slight</td>
<td>mild, moderate, severe</td>
<td></td>
</tr>
<tr>
<td>Gender (F/M)</td>
<td>4/8</td>
<td>4/7</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Age (y.o.)</td>
<td>68±10</td>
<td>68±10</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Original disease (DM/CGN/PCK/unknown)</td>
<td>7/1/2/2</td>
<td>9/1/0/1</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>HBV/HCV (n)</td>
<td>0/1</td>
<td>0/0</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Duration of HD (days)</td>
<td>23 (0–1277)</td>
<td>9 (0–5318)</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Albumin (d/dL)</td>
<td>3.2±0.6</td>
<td>3.3±0.4</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Corrected Ca (mg/dL)</td>
<td>8.8±1.1</td>
<td>8.9±0.6</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>iP (mg/dl)</td>
<td>5.0±1.8</td>
<td>5.7±1.3</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>i-PTH (pg/ml)</td>
<td>219±126</td>
<td>233±135</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>hsCRP (mg/dl)</td>
<td>0.17 (0.02–1.44)</td>
<td>0.32 (0.04–8.00)</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Ferritin (ng/ml)</td>
<td>119±84</td>
<td>130±59</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Anti-pruritic therapy (nalfurafine, urea, predonisolone, crotamiton, diphenhydramine)</td>
<td>7 (58 %)</td>
<td>3 (27 %)</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>

Values are presented as means ± SD, median (range), or numbers (percentages). P-values were calculated using the unpaired t-test, Mann-Whitney U-test, or chi-square test. DM, diabetes mellitus; CGN, chronic glomerulonephritis; PCK, polycystic kidney; hsCRP, hypersensitivity C-reactive protein.

3.2. Analysis of ion channels at the skin by RT-PCR

Expression of Cav3.2, BKCa, and Anoctamin1 was significantly higher in patients with CKD-aP. On the other hand, expression of TRPV1 was significantly decreased in those with CKD-aP. No significant difference in Cav2.2 and ASIC was observed between groups. TRPA1, Nav1.8, or Kv1.4 were not expressed (Table 4).

Table 4. Relative expression levels.

<table>
<thead>
<tr>
<th>Non-pruritus</th>
<th>Pruritus</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cav3.2</td>
<td>CACNA 1H</td>
<td>0.948 (0.660-1.809) (n=6)</td>
</tr>
<tr>
<td>Cav2.2</td>
<td>CACNA 1B</td>
<td>1.344 (0.038-19.186) (n=5)</td>
</tr>
<tr>
<td>Anoctamin1</td>
<td>TMEM 16A</td>
<td>1.094 (0.653-1.517) (n=10)</td>
</tr>
<tr>
<td>ASIC1</td>
<td>No date</td>
<td>0.796 (0.505-3.000) (n=8)</td>
</tr>
<tr>
<td>Kv1.4</td>
<td>KCNA4</td>
<td>No date</td>
</tr>
<tr>
<td>Na1.8</td>
<td>SCN10A</td>
<td>No date</td>
</tr>
<tr>
<td>TRPA1</td>
<td>No date</td>
<td>No date</td>
</tr>
</tbody>
</table>
TRPV1: 1.013 (0.804-1.223) (n=3) 0.394 (0.256-0.463) (n=3) 0.048
KCa1.1 (BKca) KCNMA1: 0.911 (0.526-1.685) (n=7) 2.657 (0.664-4.042) (n=7) 0.020

Values are expressed as median (range). P values were calculated using the unpaired t-test. BKca, large conductance in Ca²⁺-activated K⁺ channels.

4. Discussion

The primary receptors responsible are G protein-coupled receptors (GPCRs) (approximately 800 types in human), which then transmit itch signals to trimeric proteins, effectors, second messengers, as well as targets [8]. These transmitted signals ultimately affect the expression or function (i.e. sensitization) of ion channels [9,10]. These ion channels depolarize receptor potentials, and action potentials occur when the total depolarized receptor potential exceeds the threshold of voltage-dependent Na⁺ channels. Consequently, peripheral nerve signals are encoded. These signals (impulses) are transmitted to the central nervous system, including the spinal cord and brain, resulting in itching and scratching. Therefore, ion channels seem to act as output machines and molecular integrators of many pruritic inputs, which are mainly received by multiple GPCRs.

The Cav3.2 T-type calcium channel, which is only expressed in peripheral nerves at the skin, is associated with depolarization (i.e. receptor potential), action potential generation, and itching [11]. Our study demonstrated that the expression of Cav3.2 T-type calcium channels was significantly higher in patients with CKD-aP compared to those without CKD-aP. Therefore, it was speculated that the threshold of itch in patients with CKD-aP decreased because the expression of Cav3.2 T-type calcium channels in the peripheral nerve endings were increased. Many substances causing itching, such as histamine, upregulate the Cav3.2 T-type Ca²⁺ channel via GPCR [12,13]. For example, a previous study reported that agonists of the acetylcholine (Ach) muscarinic receptor, which is a GPCR, increases T-currents in rats. This report suggested that the Cav3.2 T-type Ca²⁺ channel is associated with itching in patients with atopic disease who received ACh intradermally [14]. By contrast, another study reported that Cav3.2 T-type calcium channels are more sensitive to inhibition by metals, such as zinc, copper, and nickel [15]. Furthermore, the major natural and mammalian endogenous fatty acids, including γ-linolenic acid and arachidonic acid, as well as the fully polyunsaturated ω3-fatty acids that are enriched in fish oil are potent inhibitors of the Cav3.2 T-type calcium channels [16]. This inhibitory effect may allow some patients with CKD-aP to benefit from treatment with zinc, γ-linolenic acid (ω-3), and fully polyunsaturated ω3-fatty acids [17].

Ca3.2 T-channels regulate cellular excitability in the peripheral nerve endings of nociceptors, whereas Cav2.2 (N-type Ca²⁺ channels), which also is expressed only expressed in peripheral nerves at the skin, regulate the release of neurotransmitters such as glutamate and substance P in the central terminals of nociceptor neurons in the spinal dorsal horn [18]. No statistically significant difference was observed in expression of Cav2.2 calcium channels between patients with and without CKD-aP. These findings suggest that Cav2.2 calcium channels can induce itching in central nerves, instead of peripheral nerves.

Nav1.8 contributes to action potential generation in DRG neurons in mice. Also, voltage-gated potassium (Kv) channels shape action potentials by controlling the repolarization phase, and they also determine the membrane potential and duration of the inter-spike interval [19]. Based on these findings, we measured Nav1.8 and Kv1.4, which are also expressed only expressed in peripheral nerves at the skin [20], but neither Nav1.8 nor Kv1.4 were expressed in the cutaneous peripheral nerve ending in CKD patients. This suggested that Nav1.7 (PN1), Nav1.9 (PN5), or Kv7.1-Kv7.5 (KCNQ channels) may be more associated with CKD-aP.

TRPV1 are non-selective cation channels that act as biosensors for environmental and noxious stimuli, as well as changes in temperature and conditions inside the cell. In addition to capsaicin and resiniferatoxin (RTX), protons (pH<5.7), heat (>42°C), and multiple other ligands (endogenous lipids and metabolic products of lipoxygenase) can directly activate TRPV1 [21,22]. Furthermore, indirect activation of TRPV1 by pruritogens such as histamine appears to require an intracellular signal transduction mechanism that lies downstream of GPCRs (i.e., sensitization) [23]. TRPV1 expression was significantly lower in patients with CKD-aP. Because TRPV1 is expressed not only on sensory
neurons, but also on keratinocytes and mast cells, reduced expression of TRPV1 in CKD patients with
CKD-aP is not limited to the peripheral nerve ending. Given that cutaneous TRPV1 expression
reflects its expression in cutaneous peripheral nerve endings, TRPV1 expression may be more
associated with pain rather than itching, and indeed it may inhibit itching. Khomula et al. showed
that the TRPV1 channels are downregulated, and Cav3.2 T-type channels are upregulated, under
normalgesic types of peripheral diabetic neuropathy in streptozocin-induced diabetes rats [24]. The
pathophysiology of CKD-aP may be similar to that of peripheral diabetic neuropathy.

TRPA1, which is also expressed cells other than peripheral nerve cells can be activated by
various reactive compounds, including mustard oil, cinnamaldehyde, formalin, and hydrogen
dioxide, as well as noxious cold temperature, reactive oxygen species (ROS), and inflammatory
lipids (4-hydroxynonenol). Wilson et al. showed that TRPA1 is the downstream target of both mas-
related GPCR (Mrgpr) A3 and Mrgprc11, which act as receptors for the pruritogens chloroquine and
BAM8-22, respectively [25]. But no TRPA1 expression was observed regardless of CKD-aP,
suggesting that TRPA1 may be downregulated by intracellular signals of itch such as H$_2$S [26]. Uremic
toxins stimulate the production of ROS, such as H$_2$O$_2$, in mitochondria [27,28]. And ROS sensitize
Cav3.2 T-type calcium channels and Na$^+$ channels, as well as TRPA1 and TRPV, and also increase
intracellular Ca$^{2+}$ [29,30]. Thus, uremic toxins may be related to Cav3.2 T-type calcium channels
through ROS as well as GPCRs.

In general, membrane depolarization increases the sensitivity of Anoctamin1 to an increase in
intracellular Ca$^{2+}$ [31]. Anoctamin1, which is also expressed not only on sensory neurons, but also on
keratinocytes, further enhances the depolarization of receptor potentials by efflux of anion Cl$^-$ from
the cell [32]. Compared to patients without CKD-aP, Anoctamin1 expression was increased in
patients with CKD-aP. Given that cutaneous TRPV1 expression reflects its expression in cutaneous
peripheral nerve endings, it was thought that sensitivity or expression of Anoctamin1 was increased
due to elevated intracellular Ca$^{2+}$ via Cav3.2 T-type calcium channels.

There is evidence that members of the Cav3.2 T-type calcium channel can physically and
functionally interact with the BK$_{ca}$ channels, which play a key role in controlling action potential
repolarization [33]. BK$_{ca}$ expression, which is also expressed cells other than peripheral nerve cells,
was significantly increased in patients with CKD-aP due to the increase of intracellular Ca$^{2+}$ through
the Cav3.2 T-type calcium channel. If cutaneous BK$_{ca}$ expression reflects its expression in cutaneous
peripheral nerve endings, this finding suggested that repolarization of action potentials, leading to
itching, was activated; this might affect the shape or frequency of action potential impulses related to
itching in cutaneous peripheral nerve ending. In fact, the frequency of itch impulses is less than that of
pain impulses in peripheral c-fibers [34].

ASCI was higher in patients with CKD and H$^+$ sensitivity than in healthy individuals, but the
difference was not statistically significant, suggesting no direct impact of pH on CKD-aP.

Many times in the past a new treatment option has been reported to be effective, but very soon
thereafter conflicting results appear. Most therapeutic trials have shown only limited success. I think
that this is because pruritogens mainly acts on ion channels indirectly through many GPCRs or ROS,
do not act on ion channels directly like pain stimuli,

This cohort-sectional study had some limitations. First, the total number of samples were
relatively small, which may restrict interpretation of our results.

Second, we examined ion channels specifically expressed in peripheral nerve endings (e.g.,
Cav3.2) and those expressed in keratinocytes or other sites, as well as peripheral nerve ending (e.g.
TRPV1). I think that the combination of ion channel agonists and antagonists will lead to new drug
discovery in the future. In addition to expression studies, functional studies are also needed to
investigate the physiological roles of these channels. There are many studied reports that increased
membrane expression of the ion channel parallels functional upregulation of the ion channel in
neurons [35].

5. Conclusions
It was concluded that a greater difference was observed in expression of ion channels at the skin tissue including specific for cutaneous peripheral nerve endings in CKD patients with CKD-aP than in those without CKD-aP. This upregulated expression of Cav3.2 T-type calcium channel of the peripheral nerve in patients with CKD-aP may increase generator potential related to itching and induce action potentials, resulting in encoding the amplitude, frequency and quality of impulses of the peripheral nerve neurons.


Funding: This research received no external fundings.

Acknowledgments: We thank Shun Susama, Takahiro Hirama and Takashi Kusakabe for their technical assistance.

Conflicts of Interest: The authors declare no conflict of interest.
References


